IQANOVA ATLAS™
Continuously Updated QSP–SBML Intelligence
From open mechanistic blueprints to validated combination-therapy decision engines
Academia
Pharma
Biotech
Clinical Strategy
Chapter 1
Why QSP Models Fail to Scale
Literature and clinical evidence evolve faster than models can keep pace. Most QSP assets remain static, bespoke, and poorly documented, making them difficult to adapt or validate. Combination therapies and safety considerations drive late-stage failures, yet models rarely account for these complexities. Regulators increasingly require traceability, validation, and version control—standards most QSP models don't meet.
Result: QSP models are under-used in real decision-making.
The Solution
IQANOVA ATLAS™
A living database of QSP models, encoded in SBML, continuously upgraded using new literature, new clinical studies, and structured validation workflows.
Not Software
No installation, no maintenance burden
Not Consulting
Scalable, standardized intelligence
Decision-Grade Intelligence
Mechanistic models as a subscription
What ATLAS Contains
Each ATLAS model is built to support real-world decision-making with comprehensive documentation and validation.
SBML-Encoded Structure
Mechanistic pathways in standardized format
Parameter Governance
Traceable, validated parameter sets where applicable
Clinical Endpoint Mapping
Direct connection to measurable outcomes
Versioning & Provenance
Complete audit trail for regulatory compliance
Intended Context of Use
Clear boundaries for appropriate application

AI-assisted internally, human-approved externally
Chapter 2
Free vs Paid: Clear Boundary
🟢 FREE — ATLAS Open
  • Unparameterised SBML
  • Compartments, species, reactions
  • Conceptual annotations
  • Annual static snapshot
  • Academic citation required
Purpose: Transparency, education, and community adoption
🔒 PAID — Decision-Grade Layers
  • Parameterised SBML
  • Fitted & validated SBML
  • Combination therapy & ADE models
  • Quarterly or semi-annual updates
Purpose: Real-world decision support and regulatory readiness
ATLAS Product Architecture
Four distinct layers, each building on the foundation below to deliver increasing decision-making power.
ATLAS Open
Unparameterised SBML (Free)
Structural transparency for academic use
ATLAS Curated
Parameterised, literature-aligned SBML
Ready for exploratory research
ATLAS Clinical
Fitted, validated, regulator-ready QSP
Clinical trial support and regulatory submissions
ATLAS Combo
Combination therapy & adverse drug effects
Late-stage development and safety assessment
Annual Subscription Pricing
€0
ATLAS Open
Free access to structural models
€5K
Curated Academic
Per model / year
€30K
Curated Industry
Per model / year
€120K
ATLAS Clinical
Per programme / year
€180K
Combo & Safety
€180K–€250K / year
Pricing reflects the level of validation, update frequency, and decision-grade quality required for each use case.
Chapter 3
Why Update Cadence Matters
Currency equals credibility. The frequency of updates directly impacts the reliability and relevance of models in fast-moving therapeutic areas.
6-Month Updates
Academic Tier
  • Key publications
  • Meta-analyses
  • Parameter refinements
Suitable for research environments where foundational knowledge evolves more gradually.
3-Month Updates
Industry / Clinical Tiers
  • New trials & follow-ups
  • Safety signals
  • Dose/regimen changes
  • Subgroup analyses
Essential for decision-makers who need the latest evidence to guide development strategies.
IQANOVA ATLAS™
Continuously updated, regulator-aware QSP models
From open mechanistic blueprints to validated combination-therapy decision engines